Market Overview:
The United States idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 7.30% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Idiopathic pulmonary fibrosis (IPF) is a form of progressive lung disease that causes a buildup of scar tissues in the lungs. This condition hinders the oxygen-carrying functionality of the lungs, thus resulting in breathing difficulties. IPF is diagnosed through various chest imaging evaluations, including antibody tests, lung biopsies, and pulmonary function tests. It can be treated by prescribing anti-fibrotic drugs and supportive treatment options, such as oxygen therapy and palliative care.
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
United States Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The increasing prevalence of fibrotic diseases, especially among the geriatric population, represents the key factor driving the IPF treatment market growth in the United States. Changing living standards and the increasing consumption of nicotine-based products are further catalyzing the market growth. Other than this, increasing health consciousness, rising awareness regarding the availability of effective strategies for managing IPF, and rapid advancements in diagnostic techniques are propelling the market growth. Moreover, extensive research and development (R&D) activities for introducing novel medicines are creating a positive outlook for the market in the country.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the United States idiopathic pulmonary fibrosis treatment market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on drug class and end user.
Breakup by Drug Class:
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
Breakup by End User:
- Hospitals
- Long-term Care Facilities
- Others
Breakup by Region:
- Northeast
- Midwest
- South
- West
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Million |
| Segment Coverage |
Drug Class, End User, Region |
| Region Covered |
Northeast, Midwest, South, West |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the United States idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the United States idiopathic pulmonary fibrosis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the United States idiopathic pulmonary fibrosis treatment market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 United States Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 Northeast
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Midwest
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 South
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 West
8.4.1 Market Trends
8.4.2 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Policy and Regulatory Landscape
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
List of Figures
Figure 1: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016-2021
Figure 3: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 4: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 5: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 6: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2021
Figure 7: United States: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: United States: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: United States: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: United States: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: United States: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: United States: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: United States: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: United States: Idiopathic Pulmonary Fibrosis Treatment Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: United States: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: United States: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: United States: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: United States: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Northeast: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Northeast: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Midwest: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Midwest: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: South: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: South: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: West: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: West: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: United States: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 28: United States: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 29: United States: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2021 and 2027
Table 2: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 3: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 4: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 5: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
Table 6: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players